Table 1 BMI and plasma parameters of type 2 diabetic patients before and after rosiglitazone treatment and of non-diabetic controls.
Diabetic patients (n = 11) | Controls (n = 10) | ||
|---|---|---|---|
Before treatment | After treatment | ||
BMI (kg/m2) | 30 ± 1.0 | 31 ± 1.0 | 31 ± 1.3 |
Glucose (mmol/L) | 9.2 ± 0.5a | 8.1 ± 0.5b,c | 5.8 ± 0.1 |
Insulin (mU/L) | 24.1± 3.1a | 17.2 ± 1.7b,c | 12.3 ± 0.9 |
GIR (μmol/kg/min) | 12.8± 1.3a | 20.6 ± 1.7b | 24.6 ± 2.4 |
Total cholesterol (mmol/L) | 5.4 ± 0.3 | 5.7 ± 0.4 | 5.2 ± 0.3 |
LDL cholesterol (mmol/L) | 3.5 ± 0.2 | 3.8 ± 0.4 | 3.4 ± 0.3 |
HDL cholesterol (mmol/L) | 0.93 ± 0.1 | 1.10± 0.1b | 1.14 ± 0.1 |
TCH/HDL ratio | 6.9 ± 1.1 | 5.5 ± 1.0 | 5.5 ± 1.1 |
Triglycerides (mmol/L) | 2.0 ± 0.3 | 1.5 ± 0.2b | 1.5 ± 0.4 |
FFA (mmol/L) | 509 ± 47 | 400 ± 37b | 513 ± 45.6 |